About this event

  • Date and time Fri 10 Jan 2020 from 8:30am to 7:00pm
  • Location Royal Society of Medicine
  • Organised by Oncology

Join us as we discuss and update the most current topics in the diagnosis and management of ovarian cancer from both a clinical and scientific perspective.

You will learn about:

  • The biology of ovarian cancer.
  • Progress made in the early detection of ovarian cancer.
  • Pros and cons of treatment modalities in the upfront setting.
  • The evolving role of PARP inhibitors in ovarian cancer.
  • The current evidence for immunotherapy treatments in ovarian cancer.
  • Rare ovarian cancers. 

Don't miss us covering a broad range of both clinical and scientific topics, encompassing rarer as well as more common forms of ovarian cancer. The translational data presented will be novel and some will not have been presented previously.

There are limited bursary places available for Oncology Trainees and Nurses on a first come first served basis. Please email the RSM Oncology Section oncology@rsm.ac.uk to register your interest.

 

Join in the conversation online, follow us on Twitter @RoySocMed

 

We would like to thank our exhibitor(s):

AstraZeneca.

Please note that none of the companies listed have had any influence or involvement over the agenda, content or organisation of this meeting.

 

 

Tickets

Early bird pricing available until 30 November 2019.

Member

RSM Fellow RSM Associate RSM Retired Fellow RSM Trainee RSM Student
£95.00 £55.00 £55.00 £55.00 £30.00

Non - Member

Consultant / GP Non Healthcare Professional AHP / Nurse / Midwife Trainee Student
£150.00 £95.00 £75.00 £75.00 £45.00

Key speakers

David G. Huntsman, MD, FRCPC, FCCMG

Dr. David Huntsman is a Professor in the Departments of Pathology and Laboratory Medicine and Obstetrics and Gynaecology at The University of British Columbia (UBC) and is the Dr. Chew Wei Memorial Professor of Gynaecologic Oncology.

Professor Dipanjan Chowdhury, PhD

Professor at Harvard Medical School and Chief of the Division of Genomic Stability and DNA Repair, Department of Radiation Oncology

Agenda

View the programme

Registration, tea and coffee
Welcome and introduction

Biology and early detection

Biology of ovarian cancer

Dr James Brenton, Senior Group Leader and Honorary Consultant in Medical Oncology, Cancer Research UK Cambridge Institute Cambridge Research Institute

Histopathology of early ovarian cancer

Professor Glenn McCluggage, Consultant Histopathologist, Belfast Health and Social Care Trust and Honorary Professor in Gynaecological Pathology, Queen’s University of Belfast

Breast cancer gene (BRCA) mutation signatures

Professor Dipanjan Chowdhury, Chief Division of Radiation and Genomic Stability, Dana-Farber Cancer Institute and Associate Professor, Harvard Medical School, Boston

The repertoire of non-genetic heterogeneity of serous ovarian cancer revealed by single cell sequencing of the Fallopian tube

Professor Ahmed Ahmed, Professor of Gynaecological Oncology, Director of the Ovarian Cancer Cell Laboratory, Medical Research Council Weatherall Institute of Molecular Medicine, University of Oxford

Q&A session
Tea and coffee break

Clinical session 1: Upfront therapy: Surgery and systemic anti-cancer therapy

First line systemic anti-cancer therapy

Dr Susana Banerjee, Consultant Medical Oncologist, Royal Marsden NHS Foundation Trust

Surgical management

Professor Christina Fotopoulou, Consultant Gynaecological Oncologist, Imperial College Healthcare NHS Trust

Pro upfront surgery

Professor Andreas du Bois, Director, Department for Gynecology and Gynecologic Oncology, Kliniken Essen Mitte, Germany

Pro upfront chemotherapy

Dr Marcia Hall, Consultant in Medical Oncology, East and North Hertfordshire NHS Trust

Round table discussion
Lunch

Clinical session 2: Treatment of relapsed disease

Poly-(ADP)-ribose polymerase inhibitors current use

Dr Mansoor Mirza, Chief Oncologist, Department of Oncology Rigshospitalet, Copenhagen University Hospital, Denmark

Poly-(ADP)-ribose polymerase resistance and treatment strategies

Professor Charlie Gourley, Chair of Medical Oncology and Honorary Consultant in Medical Oncology, University of Edinburgh and Clinical Director, Cancer Research UK Edinburgh Centre

Treatment of the non homologous recombination deficiency subgroups

Dr Jonathan Krell, Consultant Medical Oncologist, Imperial College Healthcare NHS Trust and Secretary, Oncology Section, Royal Society of Medicine

Role for immunotherapies in ovarian cancer

Professor George Coukos, Professor and Director, Department of Oncology, Lausanne University Hospital (UNIL CHUV) and Ludwig Institute for Cancer Research Lausanne, Switzerland

Q&A session
Tea and coffee break

Rare ovarian cancers

Sex cord stromal tumours

Professor Isabelle Ray-Coquard, Medical Oncologist, Medical Oncology Department, Institute for Clinical Science, Centre Leon Berard and Professor of Medical Oncology, University Claude Bernard Lyon I, France

Histopathology of rare ovarian cancers

Dr Baljeet Kaur, Consultant Cellular Pathologist, Imperial College Healthcare NHS Trust

Germ cell tumours

Professor Michael Seckl, Director of the Charing Cross Gestational Trophoblastic Disease and Malignant Ovarian Germ Cell Tumour Services, Imperial College Healthcare NHS Trust and President, Oncology Section, Royal Society of Medicine

Q&A session

Keynote

Cell context, mutation and ovarian cancer control

Dr David Huntsman, Dr Chew Wei Memorial Professor of Gynaecologic Oncology and Professor, Departments of Pathology and Lab Medicine and Obstetrics and Gynaecology, University of British Columbia, Vancouver

Close of meeting and drinks reception

Location

Royal Society of Medicine, 1 Wimpole St, Marylebone, London, W1G 0AE, United Kingdom